Showing 266 Results
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?
In this study from the National Pharmaceutical Council and IQVIA, researchers developed a model to understand the underlying methodological inputs that drive the substantial variation in drug…
What's Been the Bang for the Buck? Cost-Effectiveness of Health Care Spending Across Selected Conditions in the US
This study was designed to assess whether increased medical intervention spending on prevalent chronic conditions has been a good investment over time.
Prioritizing Health Care Spending: Engaging Employees in Health Care Benefit Design
A case study shows that employees who are who are meaningfully engaged in deliberating and designing their health care benefits may have a more positive view of their coverage options.
Study of U.S. Commercial Health Plans Shows Widespread Variation in Coverage and Reimbursement for Specialty Medicines
Research published in Health Affairs shows that insurance coverage and reimbursement for specialty medications varies substantially, finding that only 15.9% of drug coverage policies were consistent…
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
NPC and the Analysis Group conducted market research to explore payer views of the potential roles that existing and new alternative payment approaches could play in managing the financial risk and…
The Effect of Medical Technology Innovations on Patient Outcomes, 1990-2015: Results of a Physician Survey
A survey published in the Journal of Managed Care & Specialty Pharmacy of U.S. physicians provides insight on their perceptions regarding which medical innovation has impacted outcomes the most…
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
Evaluation of Person-level Heterogeneity of Treatment Effects in Published Multiperson N-of-1 Studies: Systematic Review and Reanalysis
To understand when and how individual treatment effects are examined, conducted and reported, this study evaluated existing multiperson N-of-1 studies, which can identify whether an intervention is…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures
Payer evaluation and coverage of pharmaceuticals and medical procedures may differ independent of their clinical benefit. Therapy access depends on factor other than cost and clinical benefit,…
Peer-reviewed Journal Editors' Views on Real-world Evidence
A study published in the International Journal of Technology Assessment in Health Care reveals that real-world evidence is considered valuable by the editors of peer-reviewed journals—if it meets…
Insurance Switching and the Mismatch Between the Costs and Benefits of New Technologies
The peer-reviewed study examined the disconnect between the short-term budget impact of a treatment and its downstream effects on payers and society.
Toward Better Value
There is a disconnect between the important role employers believe their pharmacy benefit managers (PBMs) play in helping to manage prescription drug benefits and employers’ perceptions of the…
Real-World Evidence: Useful in the Real World of United States Payer Decision-Making? How? When? And What Studies?
Research published in Value in Health on real-world evidence provides a deeper understanding of when and how managed care organizations use RWE in decision-making, and how to increase its use.
Information Wanted: Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers
Payers and providers were surveyed to understand the type of health care economic information (HCEI) they desire and value in the current and future health care environment, as well as the potential…
Optimization of Medication Use at Accountable Care Organizations
This study assesses a broad range of factors related to how accountable care organizations optimize medication use and meet financial and quality metrics.
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study
Researchers conducted cross-framework comparisons of multiple myeloma assessments using four value assessment frameworks and examined the consistency of findings across three case studies.
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Improving Oncology Quality Measurement in Accountable Care
This comprehensive white paper from the National Pharmaceutical Council and Discern Health identified gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities…
Is Real World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to research…